Gliotoxin potentiates osteoblast differentiation by inhibiting nuclear factor-κB signaling

Wang,Guangye; Zhang,Xiaohai; Yu,Baoqing; Ren,Ke

doi:10.3892/mmr.2015.3524

Gliotoxin potentiates osteoblast differentiation by inhibiting nuclear factor-κB signaling

Authors:
- Guangye Wang
- Xiaohai Zhang
- Baoqing Yu
- Ke Ren
View Affiliations

Affiliations: The Third Department of Orthopaedics, Wuhu Second People's Hospital, Wuhu, Anhui 241000, P.R. China, Department of Orthopedics, Shanghai Pudong Hospital, Fudan University Pudong Medical Centre, Shanghai 201399, P.R. China, Department of Orthopedics, Nanjing General Hospital of Nanjing Military Command Region, Nanjing, Jiangsu 210002, P.R. China
Published online on: March 20, 2015 https://doi.org/10.3892/mmr.2015.3524
Pages: 877-884
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The differentiation of pluripotent mesenchymal stem cells to mature osteoblasts is crucial for the maintenance of the adult skeleton. In rheumatic arthritis, osteoblast differentiation is impaired by the overproduction of cytokine tumor necrosis factor (TNF)‑α. It has been demonstrated that TNF‑α is able to inhibit osteoblast differentiation through the activation of nuclear factor (NF)‑κB signaling. As a result of the critical role of TNF‑α and NF‑κB in the pathogenesis of bone‑loss associated diseases, these factors are regarded as key targets for the development of therapeutic agents. In the current study, the role of the NF‑κB inhibitor gliotoxin (GTX) in the regulation of osteoblast differentiation was evaluated. The non‑toxic GTX doses were determined to be ≤3 µg/ml. It was revealed that GTX was able to block TNF‑α‑induced inhibition of osteoblast differentiation, as indicated by alkaline phosphatase (ALP) activity and ALP staining assays, as well as the expression levels of osteoblast‑associated genes Col I, Ocn, Bsp, Runx2, Osx and ATF4. Additionally, it was identified that gliotoxin directly promoted bone morphogenetic protein‑2‑induced osteoblast differentiation. GTX was found to inhibit the accumulation of NF‑κB protein p65 in the nucleus and reduce NF‑κB transcriptional activity, suggesting that GTX potentiated osteoblast differentiation via the suppression of NF-κB signaling.

View Figures

View References

1	Uccelli A, Moretta L and Pistoia V: Mesenchymal stem cells in health and disease. Nat Rev Immunol. 8:726–736. 2008. View Article : Google Scholar
2	Zaidi M: Skeletal remodeling in health and disease. Nat Med. 13:791–801. 2007. View Article : Google Scholar : PubMed/NCBI
3	Huang W, Yang S, Shao J and Li YP: Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci. 12:3068–3092. 2007. View Article : Google Scholar : PubMed/NCBI
4	Karsenty G, Kronenberg HM and Settembre C: Genetic control of bone formation. Annu Rev Cell Dev Biol. 25:629–648. 2009. View Article : Google Scholar : PubMed/NCBI
5	Baum R and Gravallese EM: Impact of inflammation on the osteoblast in rheumatic diseases. Curr Osteoporos Rep. 12:9–16. 2014. View Article : Google Scholar :
6	Walsh NC and Gravallese EM: Bone remodeling in rheumatic disease: a question of balance. Immunol Rev. 233:301–312. 2010. View Article : Google Scholar : PubMed/NCBI
7	Walsh NC, Reinwald S, Manning CA, et al: Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 24:1572–1585. 2009. View Article : Google Scholar : PubMed/NCBI
8	Cenci S, Weitzmann MN, Roggia C, et al: Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest. 106:1229–1237. 2000. View Article : Google Scholar : PubMed/NCBI
9	Roggia C, Gao Y, Cenci S, et al: Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA. 98:13960–13965. 2001. View Article : Google Scholar : PubMed/NCBI
10	Canalis E: Effects of tumor necrosis factor on bone formation in vitro. Endocrinology. 121:1596–1604. 1987. View Article : Google Scholar : PubMed/NCBI
11	Gilbert L, He X, Farmer P, et al: Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 141:3956–3964. 2000.PubMed/NCBI
12	Li Y, Li A, Strait K, Zhang H, Nanes MS and Weitzmann MN: Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. J Bone Miner Res. 22:646–655. 2007. View Article : Google Scholar : PubMed/NCBI
13	Chang J, Wang Z, Tang E, et al: Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med. 15:682–689. 2009. View Article : Google Scholar : PubMed/NCBI
14	Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 104:487–501. 2001. View Article : Google Scholar : PubMed/NCBI
15	Dempsey PW, Doyle SE, He JQ and Cheng G: The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 14:193–209. 2003. View Article : Google Scholar : PubMed/NCBI
16	Novack DV: Role of NF-κB in the skeleton. Cell Res. 21:169–182. 2011. View Article : Google Scholar
17	Kular J, Tickner J, Chim SM and Xu J: An overview of the regulation of bone remodelling at the cellular level. Clin Biochem. 45:863–873. 2012. View Article : Google Scholar : PubMed/NCBI
18	Raggatt LJ and Partridge NC: Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 285:25103–25108. 2010. View Article : Google Scholar : PubMed/NCBI
19	Xu J, Wu HF, Ang ES, et al: NF-kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev. 20:7–17. 2009. View Article : Google Scholar
20	Scharf DH, Heinekamp T, Remme N, Hortschansky P, Brakhage AA and Hertweck C: Biosynthesis and function of gliotoxin in Aspergillus fumigatus. Appl Microbiol Biotechnol. 93:467–472. 2012. View Article : Google Scholar
21	Kupfahl C, Ruppert T, Dietz A, Geginat G and Hof H: Candida species fail to produce the immunosuppressive secondary metabolite gliotoxin in vitro. FEMS Yeast Res. 7:986–992. 2007. View Article : Google Scholar : PubMed/NCBI
22	Kosalec I, Puel O, Delaforge M, et al: Isolation and cytotoxicity of low-molecular-weight metabolites of Candida albicans. Front Biosci. 13:6893–6904. 2008. View Article : Google Scholar : PubMed/NCBI
23	Sutton P, Newcombe NR, Waring P and Müllbacher A: In vivo immunosuppressive activity of gliotoxin, a metabolite produced by human pathogenic fungi. Infect Immun. 62:1192–1198. 1994.PubMed/NCBI
24	Pahl HL, Krauss B, Schulze-Osthoff K, et al: The immuno-suppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med. 183:1829–1840. 1996. View Article : Google Scholar : PubMed/NCBI
25	Kroll M, Arenzana-Seisdedos F, Bachelerie F, Thomas D, Friguet B and Conconi M: The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem Biol. 6:689–698. 1999. View Article : Google Scholar : PubMed/NCBI
26	López-Franco O, Suzuki Y, Sanjuán G, et al: Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. Am J Pathol. 161:1497–1505. 2002. View Article : Google Scholar : PubMed/NCBI
27	Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
28	Hur JM, Yun HJ, Yang SH, Lee WY, Joe MH and Kim D: Gliotoxin enhances radiotherapy via inhibition of radiation-induced GADD45a, p38 and NFkappaB activation. J Cell Biochem. 104:2174–2184. 2008. View Article : Google Scholar : PubMed/NCBI
29	Goldring SR and Gravallese EM: Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol. 12:195–199. 2000. View Article : Google Scholar : PubMed/NCBI
30	Krum SA, Chang J, Miranda-Carboni G and Wang CY: Novel functions for NFkappaB: inhibition of bone formation. Nat Rev Rheumatol. 6:607–611. 2010. View Article : Google Scholar : PubMed/NCBI
31	Soysa NS and Alles N: NF-kappaB functions in osteoclasts. Biochem Biophys Res Commun. 378:1–5. 2009. View Article : Google Scholar
32	Ozaki K, Takeda H, Iwahashi H, Kitano S and Hanazawa S: NF-kappaB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett. 410:297–300. 1997. View Article : Google Scholar : PubMed/NCBI
33	Trebec-Reynolds DP, Voronov I, Heersche JN and Manolson MF: VEGF-A expression in osteoclasts is regulated by NF-kappaB induction of HIF-1alpha. J Cell Biochem. 110:343–351. 2010.PubMed/NCBI